Suchergebnisse - "Tan, D S W"

PubPharm (30)

1

Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region : a report from the APODDC working group

enthalten in: ESMO open | 2023

von Loong, H. | Shimizu, T. | Prawira, A. | +18

2

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma : dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

enthalten in: ESMO open | 2023

von Rodon Ahnert, J. | Tan, D. | Garrido-Laguna, I. | +13

3

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy : update from the ARROW trial

enthalten in: Annals of oncology | 13 August 2022

von Griesinger, F. | Curigliano, G. | Thomas, M. | +23

4

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy : update from the ARROW trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Griesinger, F. | Curigliano, G. | Thomas, M. | +23

CommentIn: Nat Rev Clin Oncol. 2022 Oct;19(10):615. - PMID 35999290

5

Trials without borders-decentralized trials and ensuring access to novel cancer therapies during a global pandemic

enthalten in: ESMO open | 2022

von Tan, A. | Tan, T. | Saw, S. | +6

CommentOn: ESMO Open. 2022 Feb;7(1):100339. - PMID 34953404

6

Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2022

von Tan, D. | Thomas, M. | Kim, D. | +12

7

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Schoenfeld, A. | Antonia, S. | Awad, M. | +15

CommentIn: Ann Oncol. 2021 Dec;32(12):1463-1465. - PMID 34610278

8

Co-targeting the VEGF axis and immune checkpoints in NSCLC : back to the future

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Saw, S. | Tan, D.

CommentOn: Ann Oncol. 2021 Sep;32(9):1137-1147. - PMID 34139272

9

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Lin, J. | Liu, S. | McCoach, C. | +16

CommentIn: Ann Oncol. 2020 Dec;31(12):1599-1600. - PMID 33045324

10

Managing cancer patients during the COVID-19 pandemic : an ESMO multidisciplinary expert consensus

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Curigliano, G. | Banerjee, S. | Cervantes, A. | +76